Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies.
exercise
hypoxia
renal medullary carcinoma
risk factor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Nov 2021
30 Nov 2021
Historique:
received:
26
10
2021
revised:
25
11
2021
accepted:
28
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
Renal medullary carcinoma (RMC) is a lethal malignancy affecting individuals with sickle hemoglobinopathies. Currently, no modifiable risk factors are known. We aimed to determine whether high-intensity exercise is a risk factor for RMC in individuals with sickle cell trait (SCT). We used multiple approaches to triangulate our conclusion. First, a case-control study was conducted at a single tertiary-care facility. Consecutive patients with RMC were compared to matched controls with similarly advanced genitourinary malignancies in a 1:2 ratio and compared on rates of physical activity and anthropometric measures, including skeletal muscle surface area. Next, we compared the rate of military service among our RMC patients to a similarly aged population of black individuals with SCT in the U.S. Further, we used genetically engineered mouse models of SCT to study the impact of exercise on renal medullary hypoxia. Compared with matched controls, patients with RMC reported higher physical activity and had higher skeletal muscle surface area. A higher proportion of patients with RMC reported military service than expected compared to the similarly-aged population of black individuals with SCT. When exposed to high-intensity exercise, mice with SCT demonstrated significantly higher renal medulla hypoxia compared to wild-type controls. These data suggest high-intensity exercise is the first modifiable risk factor for RMC in individuals with SCT.
Identifiants
pubmed: 34885132
pii: cancers13236022
doi: 10.3390/cancers13236022
pmc: PMC8656882
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : The University of Texas MD Anderson Cancer Center
ID : Physician-Scientist Award
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : United States Department of Defense
ID : W81XWH1810570
Organisme : American Society of Clinical Oncology
ID : Career Development Award
Organisme : The University of Texas MD Anderson Cancer Center
ID : Andrew Sabin Family Fellowship
Organisme : NIEHS NIH HHS
ID : P30 ES030285
Pays : United States
Organisme : The University of Texas MD Anderson Cancer Center
ID : Khalifa Scholar Award
Références
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):418-425
pubmed: 30504341
Am J Prev Med. 2011 Dec;41(6 Suppl 4):S435-9
pubmed: 22099370
JAMA. 1974 Jun 3;228(10):1279
pubmed: 4406521
Med Sci Sports Exerc. 2010 Nov;42(11):1987-94
pubmed: 20386338
Exp Gerontol. 1996 May-Jun;31(3):387-92
pubmed: 9415121
Mod Pathol. 2019 Sep;32(9):1329-1343
pubmed: 30980040
BMC Cancer. 2017 Feb 14;17(1):130
pubmed: 28193264
Circulation. 2013 Nov 12;128(20):2259-79
pubmed: 24126387
Clin Genitourin Cancer. 2017 Dec;15(6):e987-e994
pubmed: 28558987
Clin Genitourin Cancer. 2019 Feb;17(1):1-6
pubmed: 30287223
Clin Genitourin Cancer. 2021 Jun;19(3):271.e1-271.e7
pubmed: 32893127
J Appl Physiol (1985). 2012 May;112(9):1445-53
pubmed: 22323645
Clin Genitourin Cancer. 2021 Dec;19(6):e401-e408
pubmed: 34625389
Med Oncol. 2015 Mar;32(3):56
pubmed: 25638467
Genome Med. 2021 Jul 14;13(1):114
pubmed: 34261517
Pediatr Blood Cancer. 2015 Oct;62(10):1694-9
pubmed: 26053587
Clin Genitourin Cancer. 2021 Apr;19(2):103-116
pubmed: 33358151
Clin Cancer Res. 2018 May 1;24(9):2044-2049
pubmed: 29440190
Eur Urol Focus. 2019 Sep;5(5):756-787
pubmed: 29576530
Epidemiology. 2004 Sep;15(5):529-35
pubmed: 15308951
Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):105-10
pubmed: 16373502
Nutr Clin Pract. 2017 Feb;32(1):30-39
pubmed: 28124947
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277
Cancer Cell. 2020 May 11;37(5):720-734.e13
pubmed: 32359397
Int J Epidemiol. 2016 Dec 1;45(6):1887-1894
pubmed: 28089956
Eur Urol. 2016 Sep;70(3):458-66
pubmed: 26149669
Cancers (Basel). 2021 Apr 30;13(9):
pubmed: 33946504
Urology. 2017 Oct;108:114-121
pubmed: 28705573
J Physiol. 2017 May 1;595(9):2915-2930
pubmed: 27748956
Elife. 2019 Mar 12;8:
pubmed: 30860482
JAMA. 2011 Aug 17;306(7):737-45
pubmed: 21846855
BMJ Open Gastroenterol. 2016 Oct 18;3(1):e000097
pubmed: 27843571
BJU Int. 2017 Dec;120(6):782-792
pubmed: 27860149
Mol Cell Oncol. 2020 Jun 23;7(5):1777060
pubmed: 32944636
Am J Surg Pathol. 1995 Jan;19(1):1-11
pubmed: 7528470
Eur Urol. 2016 Jun;69(6):1055-61
pubmed: 26433572
Haematologica. 2019 Jun;104(6):1106-1111
pubmed: 31097635